New advances on prostate carcinogenesis and therapies: Involvement of EGF-EGFR transduction system

Growth Factors

Volumn 21, Issue 1, 2003, Pages 1-14

  Mimeault, Murielle ^a   Pommery, Nicole ^a   Hénichart, Jean Pierre ^a  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

Author keywords

Anticarcinogenic therapies; Apoptotic death; EGF EGFR system; Prostate carcinogenesis; Tumor growth and metastasis

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS INHIBITOR; ARACHIDONIC ACID; CANERTINIB; CETUXIMAB; CISPLATIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FINASTERIDE; FLUTAMIDE; G PROTEIN COUPLED RECEPTOR; GEFITINIB; MITOGENIC AGENT; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PACLITAXEL; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RESISTANCE; CARCINOGENESIS; CAUSE OF DEATH; CELL SURVIVAL; HUMAN; INTRACELLULAR SPACE; IONIZING RADIATION; MALE; METASTASIS; MITOGENESIS; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; EPIDERMAL GROWTH FACTOR; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; PROTEIN KINASE C; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0038758829     PISSN: 08977194     EISSN: None     Source Type: Journal    
DOI: 10.1080/0897719031000094921     Document Type: Review

References (165)

1. Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascara, J.M., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., Nicholson, R.I. and Baselga, J. (2002) "Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequence of receptor inhibition", J. Clin. Oncol. 20, 110-124.
2. Alper, O., Hacker, N.F. and Cho-Chung, Y. (1999) "Protein kinase A-Iα subunit-directed antisense inhibition of ovarian cancer cell growth: cross-talk with tyrosine kinase signaling pathway", Oncogene 18, 4999-5004.
3. Anderson, R.G.W. (1998) "The caveolae membrane system", Annu. Rev. Biochem. 67, 199-225.
4. Aquilina, J.W., Lipsky, J.J. and Bostwick, D.G. (1997) "Androgen deprivation as a strategy for prostate cancer chemoprevention", J. Natl Cancer Inst. 89, 689-696.
5. Attiga, F.A., Fernandez, P.M., Weeraratna, A.T., Manyak, M.J. and Patierno, S.R. (2000) "Inhibitors of prostanglandin synthesis inhibit human tumor cell invasiveness and reduce the release of matrix metalloproteases", Cancer Res. 60, 4629-4637.
6. Bakhle, Y.S. (2001) "COX-2 and cancer: a new approach to an old problem", Br. J. Pharmacol. 134, 1137-1150.
7. Banerjee, P-P., Banerjee, S. and Brown, T.R. (2002) "Bcl-2 protein expression correlates with cell survival and androgen independence in rat prostatic lobes", Endocrinology 143, 1825-1832.
8. Barki-Harrington, L. and Daaka, Y. (2001) "Bradykinin induced mitogenesis of androgen independent prostate cancer cells", J. Urol. 165, 2121-2125.
9. Barton, J., Blackledge, G. and Wakeling, A. (2001) "Growth factors and their receptors: new targets for prostate cancer therapy", Urology 58, 114-122.
10. Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D.G., Kaye, S.B., Gianni, L., Harris, A., Bjork, T., Averbuch, S.D., Feyereislova, A., Swaisland, H., Rojo, F. and Albanell, J. (2002) "Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine inhibitor, in patients with five selected solid tumor types", J. Clin. Oncol. 20, 4276-4278.
11. Bello-DeOcampo, D., Kleinman, H.K. and Webber, M.M. (2001) "The role of alpha 6 and beta 1 integrin and EGF in normal and malignant acinar morphogenesis of human prostatic epithelial cells", Mutat. Res. 480-481, 209-217.
12. Bergan, R.C., Waggle, D.H., Carter, S.K., Horak, I., Slichenmyer, W. and Meyers, M. (2001) "Tyrosine kinase inhibitors and signal transduction modulators: rationale and current status as chemopreventive agents for prostate cancer", Urology 57, 77-80.
13. Bianco, C., Bianco, R., Tortora, G., Damiano, V., Guerrieri, P., Montemaggi, P., Mendelsohn, J., De Placido, S., Bianco, A.R. and Ciardiello, F. (2000) "Antitumor activity of combined treatment of human cancer with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide", Clin. Cancer Res. 6, 4343-4350.
14. Brown, D.A. and London, E. (2000) "Structure and function of sphingolipid- and cholesterol-rich membrane rafts", J. Biol. Chem. 275, 17221-17224.
15. Bruchovsky, N., Klotz, L.H., Sadar, M., Crook, J.M., Hoffard, D., Godwin, L., Warkentin, M., Gleave, M.E. and Goldenberg, S.L. (2000) "Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations", Mol. Urol. 4, 191-199.
16. Chan, K.C., Knox, W.F., Gee, J.M., Morris, J., Nicholson, R.I., Potten, C.S. and Bundred, N.J. (2002) "Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast", Cancer Res. 62, 122-128.
17. Chaudhary, K.S., Abel, P.D. and Lalani, E.N. (1999) "Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention", Environ. Health Perspect. 107, 49-57.
18. 2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cells", Br. J. Cancer 82, 2000-2006.
19. Chen, T., Cho, R.W., Stork, P.J. and Weber, M.J. (1999) "Elevation of cyclic adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells", Cancer Res. 59, 213-218.
20. Chi, K.N., Gleave, M.E., Klasa, R., Murray, N., Bryce, C., Lopes de Menezes, D.E., D'Aloisio, S. and Tolcher, A.W. (2001) "A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer", Clin. Cancer Res. 7, 3920-3927.
21. Cho, Y.S., Lee, Y.N. and Cho-Chung, Y.S. (2000) "Biochemical characterization of extracellular cAMP-dependent protein kinase as a tumor marker", Biochem. Biophys. Res. Commun. 278, 679-684.
22. Cho, Y.S., Kim, M.K., Tan, L., Srivastava, R., Agrawal, S. and Cho-Chung, Y.S. (2002) "Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation. Bax up-regulation, and Bad-hypophosphorylation", Clin. Cancer Res. 8, 607-614.
23. Ciardiello, F. and Tortora, G. (1998) "Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications", Clin. Cancer Res. 4, 821-828.
24. Ciardiello, F. (2000) "Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents", Drugs 60, 25-32.
25. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., De Placido, S., Bianco, A.R. and Tortora, G. (2000) "Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor", Clin. Cancer Res. 6, 2053-2063.
26. Coffey, R.N., Watson, R.W., Hegarty, P.K., Waston, C.L., Wolohan, L., Brady, H.R., O'Keane, C. and Fitzpatrick, J.M. (2001) "Priming prostate carcinoma cells for increased apoptosis is associated with up-regulation of the caspases", Cancer 92, 2297-2308.
27. Coffey, R.N., Watson, R.W., O'Neill, A.J., Mc Eleny, K. and Fitzpatrick, J.M. (2002) "Androgen-mediated resistance to apoptosis", Prostate 53, 300-309.
28. Condorelli, F., Canonico, P.L. and Sortino, M.A. (1999) "Distinct effects of ceramide-generating pathways in prostate adenocarcinoma", Br. J. Pharmacol. 127, 75-84.
29. Coroneos, E., Martinez, M., McKenna, S. and Kester, M. (1995) "Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines. Implications for cellular proliferation and differentiation", J. Biol. Chem. 270, 23305-23309.
30. Cox, M.E., Deeble, P.D., Bissonette, E.A. and Parsons, S.J. (2000) "Activated 3′,5′-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line", J. Biol. Chem. 275, 13812-13818.
31. Cuendet, M. and Pezzuto, J.M. (2000) "The role of cyclooxygenase and lipoxygenase in cancer chemoprevention", Drug Metabol. Drug Interact. 17, 109-157.
32. Culig, Z., Hobisch, A., Hittmair, A., Peterziel, H., Radmayr, C., Bartsch, G., Cato, A.C. and Klocker, H. (1997) "Hyperactive androgen receptor in prostrate cancer: what does it mean for new concepts?", Histol. Histopathol. 12, 781-786.
33. Culig, Z., Hobisch, A., Bartsch, G. and Klocker, H. (2000) "Expression and function of androgen receptor in carcinoma of the prostate", Microsc. Res. Tech. 51, 447-455.
34. Cvijic, M.E., Kita, T., Shih, W., DiPaola, R.S. and Chin, K.V. (2000) "Extracellular catalytic subunit activity of the cAMP-dependent protein kinase in prostate cancer", Clin. Cancer Res. 6, 2309-2317.
35. Daaka, Y. (2002) "Mitogenic action of LPA in prostate", Biochim. Biophys. Acta 1582, 265-269.
36. Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. and Greenberg, M.E. (1997) "Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery", Cell 91, 231-241.
37. De Bellis, A., Ghiandi, P., Comerci, A., Fiorelli, G., Grappone, C., Milani, S., Salerno, R., Marra, F. and Serio, M. (1996) "Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-alpha in human hyperplastic prostate tissue: expression and cellular localization", J. Clin. Endocr. Metab. 81, 4148-4154.
38. Del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. and Nunez, G. (1997) "Interleukin-3 induced phosphorylation of BAD through the protein kinase Akt", Science 278, 687-689.
39. Demers, R.Y., Tiwari, A., Wei, J., Weiss, L.K., Severson, R.K. and Montie, J. (2001) "Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality", Cancer 92, 2309-2317.
40. De Miguel, P., Royuela, M., Bethencourt, R., Ruiz, A., Fraile, B. and Paniagua, R. (1999) "Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates", Cytokine 11, 722-727.
41. Denmeade, S.R. and Isaacs, J.T. (1996) "Activation of programmed (apoptotic) cell death for the treatment of prostate cancer", Adv. Pharmacol. 35, 281-306.
42. Di Lorenzo, G., Tortora, G., D'Armiento, F.P., De Rosa, G., Staibano, S., Autorino, R., D'Armiento, M., De Laurentiis, M., De Placido, S., Catalano, G., Bianco, A.R. and Ciardiello, F. (2002) "Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer", Clin. Cancer Res. 8, 3438-3444.
43. Dong, J., Opresko, L.K., Dempsey, P.J., Lauffenburger, D.A., Coffey, R.J. and Wiley, H.S. (1999) "Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor", Proc. Natl Acad. Sci. (USA) 96, 6235-6240.
44. Dorai, T., Gehani, N. and Katz, A. (2000) "Therapeutic potential of curcumin in human prostate cancer II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein", Mol. Urol. 4, 1-6.
45. Dorai, T., Cao, Y.C., Dorai, B., Buttyan, R. and Katz, A.E. (2001) "Therapeutic potential of curcumin in human prostate cancer III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo", Prostate 47, 293-303.
46. Dotzlaw, H., Moehren, U., Mink, S., Cato, A.C., Iniguez Lluhi, J.A. and Baniahmad, A. (2002) "The amino terminus of the human AR is target for corepressor action and antihormone agonism", Mol. Endocrinol. 16, 661-673.
47. Edamatsu, H., Gau, C.L., Nemoto, T., Guo, I. and Tamanoi, F. (2000) "Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines", Oncogene 19, 3059-3068.
48. Engedal, N. and Saatcioglu, F. (2000) "Ceramide-induced cell death in the prostate cancer cell line LNCaP has both necrotic and apoptotic features", Prostate 46, 289-297.
49. Feldman, B.J. and Feldman, D. (2001) "The development of androgen-independent prostate cancer", Nat. Rev. Cancer 1, 34-45.
50. Fishman, D., Galitzki, L., Priel, E. and Segal, S. (1997) "Epidermal growth factor regulates protein kinase A activity in marine fibrosarcoma cells: differences between metastatic and nonmetastatic tumor cell variants", Cancer Res. 57, 5410-5415.
51. Fujita, H., Koshida, K., Keller, E.T., Takahashi, Y., Yoshimito, T., Namiki, M. and Mizokami, A. (2002) "Cyclooxygenase-2 promotes prostate cancer progression", Prostate 53, 232-240.
52. Gallardo, G., Tabraue, C., Quintana, J., Lopez-Bianco, F., Cabrera, J., Diaz, R., Estevez, F., Ruiz de Galarreta, C.M., Fanjul, L.F. and Santana, P. (2000) "Regulation by ceramide of epidermal growth factor signal transduction and mitogenesis in cell lines overespressing the growth factor receptor", Cell Mol. Biol. 46, 1305-1312.
53. Garzotto, M., Haimovitz-Friedman, A., Liao, W.C., White-Jones, M., Huryk, R., Heston, W.D., Cardon-Cardo, C., Kolesnick, R. and Fuks, Z. (1999) "Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthetase", Cancer Res. 59, 5194-5201.
54. Gewies, A., Rokhlin, O.W. and Cohen, M.B. (2000) "Ceramide induces cell death in the human prostatic carcinoma cell lines PC3 and DU145 but does not seem to be involved in Fas-mediated apoptosis", Lab. Investig. 80, 671-676.
55. Ghosh, P.M., Bedolla, R., Mikhailova, M. and Kreisberg, J.I. (2002) "RhoA-dependent murine prostate cancer cell proliferation and apoptosis: role of protein kinase Czeta", Cancer Res. 62, 2630-2636.
56. Gil-Diez de Medina, S., Salomon, L., Colombel, M., Abbou, C.C., Bellot, J., Thiery, J.P., Radvanyi, F., Van der Kwast, T.H. and Chopin, D.K. (1998) "Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer", Hum. Pathol. 29, 1005-1012.
57. Gleave, M.E., Zeilweger, T., Chi, K., Miyake, H., Kiyama, S., July, I. and Leung, S. (2002) "Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensibility", Invest. New Drug 20, 145-158.
58. Glynne-Jones, E., Goddard, L. and Harper, M.E. (1996) "Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue", Hum. Pathol. 27, 688-694.
59. Graff, J.R. (2002) "Emerging targets in the AKT pathways for treatment of androgen-independent prostatic adenocarcin-oma", Expert Opin. Ther. Targets 6, 103-113.
60. Gschwind, A., Zwick, E., Prenzel, N., Leserer, M. and Ullrich, A. (2001) "Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for inter-receptor signal transmission", Oncogene 20, 1594-1600.
61. Hafner, S., Adler, H.S., Mischak, H., Janosch, P., Heidecker, G., Wolfman, A., Piggig, S., Lohse, M., Ueffing, M. and Kolch, W. (1994) "Mechanism of inhibition of Raf-1 by protein kinase A", Mol. Cell. Biol. 14, 6696-6703.
62. Harper, M.E., Goddard, L., Glynne-Jones, E., Assender, J., Dutkowski, C.M., Barrow, D., Dewhurst, O.L., Waketing, A.E. and Nicholson, R.I. (2002) "Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor", Prostate 52, 59-68.
63. Hellerstedt, B-A. and Pienta, K.J. (2002) "The current state of hormonal therapy for prostate cancer CA", Cancer J. Clin. 52, 154-179.
64. Herbst, R.S. (2002) "ZD1839: targeting the epidermal growth factor receptor in cancer therapy", Expert Opin. Investig. Drugs 11, 837-849.
65. Herrmann, J.L., Menter, D.G., Beham, A., Von Eschenbach, A. and McDonnell, T.G. (1997) "Regulation of lipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells", Exp. Cell. Res. 234, 442-451.
66. Hoosein, N.M., Logothetis, C.J. and Chung, L.W. (1993) "Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells", J. Urol. 149, 1209-1213.
67. Huang, H. and Tindall, D.J. (2002) "The role of the androgen receptor in prostate cancer", Crit. Rev. Eukaryot. Gene Expr. 12, 193-207.
68. Johnson, K.P., Rowe, G.C., Jackson, B.A., d'Agustino, J.L., Campbell, P.E., Guillory, B.O., Williams, M.V., Matthews, Q.L., McKay, J., Charles, G.M., Vet-ret, C.R., Deleon, M., Johnson, D.E. and Cooke, D.B. (2002) "Novel antineoplastic isochalcones inhibit the expression of cyclooxygenase 1,2 and EGF in human prostate cancer line LNCaP", Cell. Mol. Biol. 47, 1039-1045.
69. Kamijo, T., Sato, T., Nagatomi, Y. and Kitamura, T. (2001) "Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines", Int. J. Urol. 8, S35-S39.
70. Karashima, T., Sweeney, P., Slaton, J.M., Kim, S.J., Kedar, D., Izawa, J.I., Fan, Z., Pettaway, C., Hicklin, D.J., Shuin, T. and Dinney, C.P. (2002) "Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice", Clin. Cancer Res. 8, 1253-1264.
71. Karp, J.E., Chiarodo, A., Brawley, O. and Kelloff, G.F. (1996) "Prostate cancer prevention: investigational approaches and opportunities", Cancer Res. 56, 5547-5556.
72. Karunagaran, D., Tzahar, E., Beerli, R.R., Chen, X., Graus-Porta, D., Ratzkin, B.J., Seger, R., Hynes, N.E. and Yarden, Y. (1996) "ErbB-2 is a commun auxiliary subunit of NDF and EGF receptors: implications for breast cancer", EMBO J. 15, 254-264.
73. Kelloff, G.J., Lieberman, R., Steele, V.E., Boone, C.W., Lubel, R.A., Kepelovich, I., Malone, W.A., Crowell, J.A., Higley, H.R. and Sigman, C.C. (2001) "Agents, biomarkers, and cohorts for chemopreventive agent development in prostrate cancer", Urology 57, 46-51.
74. Kim, H.G., Kassis, I., Sorrto, J.C., Turner, T. and Wells, A. (1999) "EGF receptor signaling in prostate morphogenesis and tumorigenesis", Histol. Histopathol. 14, 1175-1182.
75. Kim, E-S., Khuri, F.R. and Herbst, R.S. (2001) "Epidermal growth factor receptor biology (IMC-C225)", Curr. Opin. Oncol. 13, 506-513.
76. Kimura, K., Markowski, M., Bowen, C. and Gelmann, E.P. (2001) "Androgen blocks apoptosis of hormone-dependent prostate cancer cells", Cancer Res. 61, 5611-5618.
77. Kirschenbaum, A., Liu, X., Yao, S. and Levine, A.C. (2001) "The role of cyciooxygenease-2 in prostate cancer", Urology 58, 127-131.
78. Klocker, H., Culig, Z., Eder, I.E., Nessler-Menardi, C., Hobisch, A., Putz, T., Bartsch, G., Peterziel, H. and Cato, A.C. (1999) "Mechanism of androgen receptor activation and possible implications for chemoprevention trials", Eur. Urol. 35, 413-419.
79. Konety, B.R. and Nelson, J.B. (2001) "Nonandrogenic mediators of prostatic growth", Hematol. Oncol. Clin. North Am. 15, 459-476.
80. Kranenburg, O. and Moolenaar, W.H. (2001) "Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists", Oncogene 20, 1540-1546.
81. Kue, P.F. and Daaka, Y. (2000) "Essential role for G proteins in prostate cancer cell growth and signaling", J. Urol. 164, 2162-2167.
82. Kue, P.F., Taub, J.S., Harrington, L.B., Polakiewicz, R.D., Ullrich, A. and Daaka, Y. (2002) "Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells", Int. J. Cancer 102, 572-579.
83. Kumar, V.L., Majumder, P.K., Gujral, S. and Kumar, V. (1998) "Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcimatous prostate", Cancer Lett. 134, 177-180.
84. Kyprianou, N. (1994) "Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer", World J. Urol. 12, 299-303.
85. Lalani, E.N., Laniado, M.E. and Abel, P.D. (1997) "Molecular and cellular biology of prostate cancer", Cancer Metast. Rev. 16, 29-66.
86. Li, M.T., Richter, F., Chang, C., Irwin, R.J. and Huang, H. (2002) "Androgen and retinoic acid interaction in LNCaP cells, effects on cell proliferation and expression of retinoic acid receptors and epidermal growth factor receptor", BMC Cancer 2, 16.
87. Lin, J., Adam, R.M., Santiestevan, E. and Freeman, M.R. (1999) "The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells", Cancer Res. 59, 2891-2897.
88. Liu, W.K., Wong, N.L., Huang, H.M., Ho, J.K., Zhang, W.H. and Che, C.T. (2002) "Growth inhibitory activity of lemnabourside on human prostate cancer cells", Life Sci. 70, 843-853.
89. Liu, X.H., Wiley, H.S. and Merkle, A.W. (1993) "Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor", J. Clin. Endocr. Metab. 77, 1472-1478.
90. Liu, X.H., Kirschenbaum, A., Yao, S., Lee, R., Holland, J.F. and Levine, A.C. (2000) "Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo", J. Urol. 164, 820-825.
91. Liu, X.H., Kirschenbaum, A., Lu, M., Yao, S., Dosoretz, A., Holland, J.F. and Levine, A.C. (2002) "Prostaglandin E2 induces hypoxia-inducible factor-1a stabilization and nuclear localization in a prostate cancer cell line", J. Biol. Chem.
92. Lu, X.F., Tam, N.C. and Wong, Y.C. (2000) "Roles of growth factors in mediating mesenchymal influence on the cytodifferentiation of the Dunning prostatic adenocarcinoma", Tumour Biol. 21, 21-32.
93. MacDonald, A. and Habid, F.K. (1992) "Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines", Br. J. Cancer 65, 177-182.
94. Maddy, S.Q., Chisholm, G.D., Busuttil, A. and Habib, F.K. (1989) "Epidermal growth factor receptors in prostate cancer: correlation with histological differentiation of the tumour", Br. J. Cancer 60, 41-44.
95. Marinissen, M.J. and Gutkind, J.S. (2001) "G-protein-coupled receptors and signaling networks: emerging paradigms", Trends Pharmacol. Sci. 22, 368-376.
96. Melck, D., Rueda, D., Galve-Roperh, I., De Petrocellis, L., Guzman, M. and Di Marzo, V. (1999) "Involvement of the cAMP/protein kinase pathway and of mitogen-activated protein-kinase in the antiproliferative effects of anandamide in human breast cancer cells", FEBS Lett. 463, 235-240.
97. Melck, D., De Petrocellis, L., Orlando, P., Bisogno, T., Laezza, C., Bifulco, M. and Di Marzo, V. (2000) "Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation", Endocrinology 141, 118-126.
98. Mellinghoff, I.K., Tran, C. and Sawyers, C.L. (2002) "Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts", Cancer Res. 62, 5254-5259.
99. Meric, J.B., Faivre, S., Monnerat, C., diVago, N.A., Le Chevalier, T., Armand, J.P. and Raymond, E. (2000) "ZD1839: Iressa", Bull. Cancer 87, 873-876.
100. Miller, M.J. (1998) "Differential effects of protein kinase A on Ras effector pathways", Mol. Cell. Biol. 18, 3718-3726.
101. Mimeault, M. (2001) "Structure-function studies of ETS transcription factors", Crit. Rev. Oncogene 11, 227-253.
102. Mimeault, M. (2002) "New advances on structural and biological functions of ceramide in apoptotic/necrotic cell death and cancer", FEBS Lett. 530, 9-16.
103. Mimeault, M. and Bonenfant, D. (2002) "FTIR spectroscopic analyses of the temperature and pH influences on the stratum corneum lipid phase behaviors and interactions", Talanta 56, 395-405.
104. Mimeault, M., Pommery, N., Wattez, N., Bailly, C. and Henichart, J.P. (2002) "Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines. Implication of epidermal growth factor receptor down-regulation and ceramide production", Prostate.
105. Moasser, M.M., Basso, A., Averbuch, S.D. and Rosen, N. (2001) "The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells", Cancer Res. 61, 7184-7188.
106. Moscatello, D.K., Holga-Madruga, M., Godwin, A.K., Ramirez, G., Gunn, G., Zoltick, P.W., Biegel, J.A., Hayes, R.L. and Wong, A.J. (1995) "Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors", Cancer Res. 55, 5536-5539.
107. Moulder, S.L., Yakes, F.M., Muthuswamy, S.K., Bianco, R., Simpson, J.F. and Carlos, L.A. (2001) "Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2 /neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo", Cancer Res. 61, 8887-8895.
108. Myers, C.E. and Ghosh, J. (1999) "Lipoxygenase inhibition in prostate cancer", Eur. Urol. 35, 395-398.
109. Myers, R.B. and Grizzle, W.E. (1997) "Changes in biomarker expression in the development of prostatic adenocarcinoma", Biotech. Histochem. 72, 86-95.
110. Myers, R.B., Oelschlager, D., Manne, U., Coan, P-N., Weiss, H. and Grizzle, W.E. (1999) "Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma", Int. J. Cancer 82, 424-429.
111. Naruse, I., Ohmori, T., Ao, Y., Fukumoto, H., Kuroki, T., Mori, M., Saijo, I. and Nishio, K. (2002) "Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD-1859) in an EGFR-expressing multidrug-resistance cell line in vitro and in vivo", Int. J. Cancer 98, 310-315.
112. Nazareth, L.V. and Weigel, L. (1996) "Activation of the human androgen receptor through a protein kinase A signaling pathway", J. Biol. Chem. 271, 19900-19907.
113. Nesterova, M., Noguchi, K., Park, Y.G., Lee, Y.N. and Cho-Chung, Y.S. (2000) "Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein", Clin. Cancer Res. 6, 3434-3441.
114. Nie, D., Tang, K., Szekeres, K., Li, L. and Hohn, K.V. (2000) "Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications", Ann. N.Y. Acad. Sci. 905, 165-176.
115. Olapade-Olaopa, E.O., Moscatello, D.K., MacKay, E.H., Horsburgh, T., Sandhu, D.P., Terry, T.R., Wong, A.J. and Habib, F.K. (2000) "Evidence for the differential expression of a variant EGF receptor in human prostate cancer", Br. J. Cancer 82, 186-194.
116. Payne, S.G., Brindley, D.N. and Guilbert, L.J. (1999) "Epidermal growth factor inhibits ceramide-induced apoptosis and lowers ceramide levels in primary placental trophoblasts", J. Cell. Physiol. 180, 263-270.
117. KiP1 and induces G 1 arrest in prostatic carcinoma cell line DU145", Cancer Res. 56, 3666-3669.
118. Pidgeon, G.P., Kandouz, M., Meram, A. and Hohn, K.V. (2002) "Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells", Cancer Res. 62, 2721-2727.
119. Pierce, K.L., Luttrell, L.M. and Lefkowitz, R.J. (2001) "New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades", Oncogene 20, 1532-1539.
120. Pirtskhalaishvili, G. and Nelson, J.B. (2000) "Endothelium-derived factors as paracrine mediators of prostate cancer progression", Prostate 44, 77-87.
121. Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C. and Ullrich, A. (1999) "EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF", Nature 402, 884-888.
122. Prenzel, N., Zwick, E., Leserer, M. and Ullrich, A. (2000) "Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification", Breast Cancer Res. 2, 184-190.
123. Putz, T., Culig, Z., Eder, I.E., Nessler-Menardi, C., Bartsch, G., Grunicke, H., Uberall, F. and Klocker, H. (1999) "Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathways in prostate cancer cell lines", Cancer Res. 59, 227-233.
124. Ranson, M. (2002) "ZD1839 (Iressa): for more than just non-small cell lung cancer", Oncologist 7, 16-24.
125. Ripple, M.O., Henry, W.F., Rago, R.P. and Wilding, G. (1997) "Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells", J. Natl Cancer Inst. 89, 40-48.
126. Rubenstein, M., Mirochnik, Y., Chou, P. and Guinan, P. (1998) "Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides", Methods Find Exp. Clin. Pharmacol. 20, 825-831.
127. Sadar, M.D. (1999) "Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways", J. Biol. Chem. 274, 7777-7783.
128. Sadar, M.D., Hussain, M. and Bruchovsky, N. (1999) "Prostate cancer: molecular biology of early progression to androgen independence", Endocr. Relat. Cancer 6, 487-502.
129. Salido, M., Vilches, J., Lopez, A. and Roomans, G.M. (2002) "Neuropeptides bombesin and calcitonin inhibit apoptosis-related elemental changes in prostate carcinoma cell lines", Cancer 94, 368-377.
130. Schwartz, Jr, S., Caceres, C., Morote, J., De Torres, I., Rodriguez-Vallejo, J.M., Gonzalez, J. and Reventos, J. (1999) "Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis", Int. J. Oncol. 14, 367-371.
131. Seelan, R.S., Qian, C., Yokomizo, A., Bostwick, D.G., Smith, D.I. and Liu, W. (2000) "Human acid ceramidase is overexpressed but not mutated in prostate cancer", Genes Chromosomes Cancer 29, 137-146.
132. Seetharam, S., Nodzenski, E., Beckett, M.A., Heimann, R., Cha, A., Margulies, I., Pastan, I., Kufe, D.W. and Weichselbaum, R.R. (1998) "Modulation of apoptotic response of a radiation-resistant human carcinoma by Pseudomonas exotoxin-chimeric protein", Cancer Res. 58, 3215-3220.
133. Seth, D., Shaw, K., Jazayeri, J. and Leedman, P.J. (1999) "Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancers cells", Br. J. Cancer 80, 657-669.
134. 2+ transients", Endocrinology 134, 596-602.
135. Shaheen, R.M., Ahmad, A.S., Liu, W., Reinmuth, N., Jung, Y.D., Tseng, W.W., Drazan, K.E., Bucana, C.D., Hicklin, D.J. and Ellis, L.M. (2001) "Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors", Br. J. Cancer 95, 584-589.
136. Shaul, P.W. and Anderson, R.G. (1998) "Role of plasmalemma caveolae in signal transduction", Am. J. Physiol. 275, L843-L851.
137. Sherwood, E.R., Van Dongen, J.L., Wood, C.G., Liao, S., Kozlowski, J.M. and Lee, C. (1998) "Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells", Br. J. Cancer 77, 855-861.
138. Shureiqi, I. and Lippman, S.M. (2001) "Lipoxygenase modulation to reverse carcinogenesis", Cancer Res. 61, 6307-6312.
139. Slichenmyer, W.J., Elliott, W.L. and Fry, D.W. (2001) "CI-1033, a panerbB tyrosine kinase inhibitor", Semin. Oncol. 28, 80-85.
140. Sumitomo, M., Ohba, M., Asakuma, J., Asano, T., Kuroki, T. and Hayakawa, M. (2000) "Protein kinase C delta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells", J. Clin. Investig. 109, 827-836.
141. Tanji, N., Kikugawa, T. and Yokoyama, M. (2000) "Immunohistochemical study of cyclooxygenase in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 Protein expression", Anticancer Res. 20, 2313-2319.
142. Tanji, N., Aoki, K. and Yokoyama, M. (2001) "Growth factors: roles in andrology", Arch. Androl. 47, 1-7.
143. Teicher, B.A., Kakeji, Y., Ara, G., Herbst, R.S. and Northey, D. (1997) "Prostate carcinoma response to cytotoxic therapy: in vivo resistance", In vivo 11, 453-461.
144. Torring, N., Moller-Ernst, J.K., Lund, L., Nielsen, J.E., Djurhuus, J.C., Poulsen, S.S. and Nexo, E. (2002) "Possible autocrine loop of the epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: a placebo-controlled randomized study", BJU Int. 99, 583-590.
145. Tortora, G. and Ciardiello, F. (2000) "Targeting of
146. Tortora, G. and Ciardiello, F. (2002) "Protein Kinase A a target for novel integrated strategies of cancer therapy", Ann. N.Y. Acad. Sci. 968, 139-147.
147. Tortora, G., Damiano, V., Bianco, C., Baldassarre, G., Bianco, A.R., Lanfrancone, L., Pelicci, P.G. and Ciardiello, F. (1997) "The Rlalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor", Oncogene 14, 923-928.
148. Van Coppenolle, F., Le Bourhis, X., Carpentier, F., Delaby, G., Cousse, H., Raynaud, J.P., Dupouy, J.P. and Prevarskaya, N. (2000) "Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparaison with finasteride", Prostate 43, 49-58.
149. Van Meer, G. and Lisman, Q. (2002) "Sphingolipid transport; rafts and translocators", J. Biol. Chem. 277, 25855-25858.
150. Van Moorselaar, R.J. and Voest, E.E. (2002) "Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches", Mol. Cell. Endocrinol. 197, 239-250.
151. Von Haefen, C., Wieder, T., Gillissen, B., Starck, L., Graupner, V., Dorken, B. and Daniel, P.T. (2002) "Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells", Oncogene 21, 4009-4019.
152. Vossler, M.R., Yao, H., York, R.D., Pan, M.G., Rim, C.S. and Stork, P.J. (1997) "cAMP activates MAP kinase and Elk-1 through a B-Rad-, and Rap 1-dependent pathway", Cell 89, 73-82.
153. Wang, X.Z., Beebe, J.R., Pwiti, L., Bielawska, A. and Smyth, M.J. (1999) "Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy", Cancer Res. 59, 5842-5848.
154. Wang, X., Ye, H. and Jiang, H. (2000) "Influence of androgen on Bcl-2 mRNA expression in BPH tissue", Zhonghua Wai Ke Za Zhi. 39, 198-200.
155. Ware, J.L. (1999) "Growth factor network disruption in prostate cancer progression", Cancer Metast. Rev. 17, 443-447.
156. Wartenberg, M., Fischer, K., Hescheler, J. and Sauer, H. (2000) "Redox regulation of P-glycoprotein-mediated multidrug resistance in multicellular prostate tumor spheroids", Int. J. Cancer 85, 267-274.
157. Werb, Z. and Yang, Y. (1998) "A cellular striptease act", Science 282, 1279-1280.
158. Worthylake, R., Opreslo, L.K. and Wiley, H.S. (1999) "ErbB-2 amplification inhibits down-regulation and induce constitutive activation of both ErbB-2 and epidermal growth factor receptors", J. Biol. Chem. 274, 8865-8874.
159. Wu, X., Rubin, M., Fan, Z., Deblasio, T., Soos, T., Koff, A. and Mendelsonn, J. (1996) "Involvement of p27KiP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody", Oncogene 12, 1397-1403.
160. Xia, W., Lau, Y.K., Zhang, H.Z., Xiao, F.Y., Jhonson, D.A., Liu, A.R., Li, L., Katz, R.L. and Hung, M.C. (1999) "Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the out-come of oral squamous cell carcinoma than any individual family members", Clin. Cancer Res. 5, 4164-4174.
161. Xie, Y., Gibbs, T.C., Mukhin, Y.V. and Meir, K.E. (2002) "Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells", J. Biol. Chem. 277, 32516-32526.
162. Yang, X.D., Jia, X.C., Corvala, J.R.F., Wang, P. and Davis, C.G. (2001) "Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy", Crit. Rev. Oncol. Hematol. 38, 17-23.
163. KiP1 and costimulate proliferation of MDA Pca 2a and MDA Pca 2b prostate cancer cells", Clin. Cancer Res. 5, 2171-2177.
164. Zi, X., Grasso, A.W., Kung, H.J. and Agarwal, R. (1998) "A flavonoid antioxidant silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells", Cancer Res. 58, 1920-1929.
165. Zhuang, L., Lin, J., Lu, M.L., Solomon, K.R. and Freeman, M.R. (2002) "Cholesterol-rich lipid rafts mediate Akt-regulated survival in prostate cancer cells", Cancer Res. 62, 2227-2231.